CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,558	$ 5,158
Prepaid expenses and other current assets	940	1,064
Total current assets	2,498	6,222
Property and equipment, net	307	332
Operating lease right-of-use asset	198	262
Other assets	29	29
Total assets	3,032	6,845
Current liabilities:
Accounts payable	6,523	3,388
Accrued clinical trials expenses	984	5,128
Accrued compensation	1,338	943
Forward purchase agreements liquidated damages	3,000
Other accrued expenses	4,112	3,590
Total current liabilities	15,957	13,049
Convertible notes at fair value, including related party amount of $5,087 and $0, at March 31, 2024 and December 31, 2023, respectively	5,087
Warrant liability	12,000	1,447
Contingent consideration liability	168,119	104,350
Embedded forward purchase agreements and derivative liabilities	250	41,043
Total liabilities	201,413	159,889
Commitments and contingencies
Stockholders' Deficit:
Class A common stock, $0.0001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023, and 38,120,288 and 37,159,600 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	4	4
Additional paid-in capital	393,235	381,264
Subscription receivables		(60,710)
Accumulated deficit	(591,620)	(473,602)
Total stockholders' deficit	(198,381)	(153,044)
Total liabilities and stockholders' deficit	$ 3,032	$ 6,845
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor